ArticlePloS one2011
Overexpression of prothymosin alpha predicts poor disease outcome in head and neck cancer.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- CD44-SNA1 integrated cytopathology for delineation of high grade dysplastic and neoplastic oral lesions.PloS one · 2023Pooled it
- Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis.Urologic oncology · 2022Pooled it
- A systematic review of proteomic biomarkers in oral squamous cell cancer.World journal of surgical oncology · 2021Pooled it
- Aberrant expression of nuclear prothymosin α contributes to epithelial-mesenchymal transition in lung cancer.Molecular oncology · 2025Article
- HE2Gene: image-to-RNA translation via multi-task learning for spatial transcriptomics data.Bioinformatics (Oxford, England) · 2024Article
- Identification of Potential Biomarkers Using Integrative Approach: A Case Study of ESCC.SN computer science · 2023Article
- First Evidence of the Expression and Localization of Prothymosin α in Human Testis and Its Involvement in Testicular Cancers.Biomolecules · 2022Article
- Overexpression of prothymosin-α in glioma is associated with tumor aggressiveness and poor prognosis.Bioscience reports · 2022Article
- EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.Breast cancer (Tokyo, Japan) · 2021Article
- Expression of prothymosin α in lung cancer is associated with squamous cell carcinoma and smoking.Oncology letters · 2019Article
- Subcellular differential expression of Ep-ICD in oral dysplasia and cancer is associated with disease progression and prognosis.BMC cancer · 2016Article
- ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.Oncotarget · 2016Article
- Subcellular dissemination of prothymosin alpha at normal physiology: immunohistochemical vis-a-vis western blotting perspective.BMC physiology · 2016Article
- Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitamins and hormones · 2016Review
- Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer.Oncogenesis · 2015Article
- Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.Journal of translational medicine · 2015Article
- Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.PloS one · 2015Article
- Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer.International journal of clinical and experimental pathology · 2014Article
- Article
- Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundIn our recent study, tissue proteomic analysis of oral pre-malignant lesions (OPLs) and normal oral mucosa led to the identification of a panel of biomarkers, including prothymosin alpha (PTMA), to distinguish OPLs from histologically normal oral tissues. This study aimed to determine the clinical significance of PTMA overexpression in oral squamous cell hyperplasia, dysplasia and head and neck squamous cell carcinoma (HNSCC). METHODOLOGY: Immunohistochemistry of PTMA protein was performed in HNSCCs (n = 100), squamous cell hyperplasia (n = 116), dysplasia (n = 50) and histologically normal oral tissues (n = 100). Statistical analysis was carried out to determine the association of PTMA overexpression with clinicopathological parameters and disease prognosis over 7 years for HNSCC patients.
resultsOur immunohistochemical analysis demonstrated significant overexpression of nuclear PTMA in squamous cell hyperplasia (63.8%), dysplasia (50%) and HNSCC (61%) in comparison with oral normal mucosa (p(trend)<0.001). Chi-square analysis showed significant association of nuclear PTMA with advanced tumor stages (III+IV). Kaplan Meier survival analysis indicated reduced disease free survival (DFS) in HNSCC patients (p<0.001; median survival 11 months). Notably, Cox-multivariate analysis revealed nuclear PTMA as an independent predictor of poor prognosis of HNSCC patients (p<0.001, Hazard's ratio, HR = 5.2, 95% CI = 2.3-11.8) in comparison with the histological grade, T-stage, nodal status and tumor stage.
conclusionsNuclear PTMA may serve as prognostic marker in HNSCC to determine the subset of patients that are likely to show recurrence of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.